Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study

References

• Forman D, Ferlay J. The global and regional burden of cancer. In: Stewart B, Wild C, editors. World Cancer Report. 2014. Lyon: IARC, WHO; 2014. p. 16–53.
   Google Scholar
• Sorbye H, Kohne CH, Sargent DJ, et al. Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. Ann Oncol. 2007;18(10):1666–1672.
   PubMed Web of Science ®Google Scholar
• Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713–1729.
   PubMed Web of Science ®Google Scholar
• Goey KKH, Sørbye H, Glimelius B, et al. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: supported by the ARCAD Group. Eur J Cancer. 2018;100:35–45.
   PubMed Web of Science ®Google Scholar
• Therkildsen C, Bergmann TK, Henrichsen-Schnack T, et al. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol. 2014;53(7):852–864.
   PubMed Web of Science ®Google Scholar
• Passardi A, Canale M, Valgiusti M, et al. Immune checkpoints as a target for colorectal cancer treatment. Int J Mol Sci. 2017;18(6):pii: E1324.
   Web of Science ®Google Scholar
• Sorbye H, Pfeiffer P, Cavalli-Björkman N, et al. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer. 2009;115(20):4679–4687.
   PubMed Web of Science ®Google Scholar
• Sorbye H, Dragomir A, Sundström M, et al. High BRAF mutation frequency and marked survival differences in subgroups according to KRAS/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort. PLoS One. 2015;10(6):e0131046.
   PubMed Web of Science ®Google Scholar
• Uhlén M, Fagerberg L, Hallström BM, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.
   PubMed Web of Science ®Google Scholar
• Magnusson K, de Wit M, Brennan DJ, et al. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol. 2011;35(7):937–948.
   PubMed Web of Science ®Google Scholar
• Dragomir A, de Wit M, Johansson C, et al. The role of SATB2 as a diagnostic marker for tumors of colorectal origin: results of a pathology-based clinical prospective study. Am J Clin Pathol. 2014;141(5):630–638.
   PubMed Web of Science ®Google Scholar
• Liu TR, Xu LH, Yang AK, et al. Decreased expression of SATB2: a novel independent prognostic marker of worse outcome in laryngeal carcinoma patients. PLoS One. 2012;7(7):e40704.
   PubMed Web of Science ®Google Scholar
• Geng GJ, Li N, Mi YJ, et al. Prognostic value of SATB2 expression in patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2015;8(1):423–431.
   PubMed Web of Science ®Google Scholar
• Guo C, Xiong D, Yao X, et al. Decreased SATB2 expression is associated with metastasis and poor prognosis in human clear cell renal cell carcinoma. Int J Clin Exp Pathol. 2015;8(4):3710–3718.
   PubMed Web of Science ®Google Scholar
• Elebro J, Heby M, Gaber A, et al. Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma. J Transl Med. 2014;12(1):289.
   PubMedGoogle Scholar
• Eberhard J, Gaber A, Wangefjord S, et al. A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer. Br J Cancer. 2012;106(5):931–938.
   PubMed Web of Science ®Google Scholar
• Kampf C, Olsson I, Ryberg U, et al. Production of tissue microarrays, immunohistochemistry staining and digitalization within the human protein atlas. J Vis Exp. 2012;(63):pii: 3620.
   Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
   PubMed Web of Science ®Google Scholar
• Ma C, Olevian DC, Lowenthal BM, et al. Loss of SATB2 expression in colorectal carcinoma is associated with DNA mismatch repair protein deficiency and BRAF mutation. Am J Surg Pathol. 2018;42(10):1409–1417.
   PubMed Web of Science ®Google Scholar
• Mansour MA, Asano E, Hyodo T, et al. Special AT-rich sequence-binding protein 2 suppresses invadopodia formation in HCT116 cells via palladin inhibition. Exp Cell Res. 2015;332(1):78–88.
   PubMed Web of Science ®Google Scholar
• Yang MH, Yu J, Chen N, et al. Elevated microRNA-31 expression regulates colorectal cancer progression by repressing its target gene SATB2. PLoS One. 2013;8(12):e85353.
   PubMed Web of Science ®Google Scholar
• Luo LJ, Yang F, Ding JJ, et al. MiR-31 inhibits migration and invasion by targeting SATB2 in triple negative breast cancer. Gene. 2016;594(1):47–58.
   PubMed Web of Science ®Google Scholar
• Mansour MA, Hyodo T, Ito S, et al. SATB2 suppresses the progression of colorectal cancer cells via inactivation of MEK5/ERK5 signaling. FEBS J. 2015;282(8):1394–1405.
   PubMed Web of Science ®Google Scholar
• Ma YN, Zhang HY, Fei LR, et al. SATB2 suppresses non-small cell lung cancer invasiveness by G9a. Clin Exp Med. 2018;18(1):37–44.
   PubMed Web of Science ®Google Scholar
• Sun M, Zhang Q, Yang X, et al. Vitamin D enhances the efficacy of irinotecan through miR-627-mediated inhibition of intratumoral drug metabolism. Mol Cancer Ther. 2016;15(9):2086–2095.
   PubMed Web of Science ®Google Scholar
• Lipsyc M, Yaeger R. Impact of somatic mutations on patterns of metastasis in colorectal cancer. J Gastrointest Oncol. 2015;6(6):645–649.
   PubMed Web of Science ®Google Scholar
• Jang MH, Kim S, Hwang DY, et al. BRAF-mutated colorectal cancer exhibits distinct clinicopathological features from wild-type BRAF-expressing cancer independent of the microsatellite instability status. J Korean Med Sci. 2017;32(1):38–46.
   PubMed Web of Science ®Google Scholar